Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data

NCT05438888 · clinicaltrials.gov ↗

COMPLETED

Status

77814

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-valvular Atrial Fibrillation

Interventions

DRUG: Warfarin
DRUG: Apixaban

Sponsor

Pfizer